TITLE

FDA APPROVES CEPHALON TREANDA TO TREAT NON-HODGKINS LYMPHOMA

PUB. DATE
December 2008
SOURCE
Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the Treanda, bendamustine hydrochloride, from Cephalon Inc. by the U.S. Food and Drug Administration (FDA). The injectable drug is intended for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that progressed during treatment with rituximab or a rituximab-containing regimen. Data showed that the drug is effective and has a tolerable side effect among patients.
ACCESSION #
35409955

 

Related Articles

  • Cephalon wins FDA approval for lymphoma drug.  // PharmaWatch: Biotechnology;Dec2008, Vol. 7 Issue 12, p12 

    The article reports on the approval that the U.S. Food and Drug Administration (FDA) granted to Cephalon Inc.'s Treanda for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a...

  • FDA accepts Cephalon's NDA for lymphoma drug.  // PharmaWatch: Biotechnology;Apr2008, Vol. 7 Issue 4, p10 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) of Cephalon Inc. for its Treanda, a drug for treating patients with indolent B-cell non-Hodgkin's lymphoma (NHL). It was that FDA accepted Cephalon's NDA after the drug successfully...

  • FDA Gives Thumbs Down to Nuvigil for Jet Lag.  // Bioworld Week;1/3/2011, Vol. 19 Issue 1, p3 

    The article reports on the disapproval of the U.S. Food and Drug Administration (FDA) to the sleep disorder drug Nuvigil of Cephalon Inc. to be medicated for jet lag.

  • FDA approves lenalidomide for treatment of mantle cell lymphoma.  // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p9 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the immunomodulating agent lenalidomide for the treatment of mantle cell lymphoma.

  • FDA APPROVES TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA.  // Medical Economics;3/10/2014, Vol. 91 Issue 5, p12 

    The article reports on accelerated approval granted by the U.S. Food and Drug Administration to Imbruvica to treat mantle cell lymphoma if patients had received one prior therapy.

  • Cephalon gains FDA approval for expanded use of Provigil.  // PharmaWatch: CNS;March 2004, Vol. 3 Issue 3, p18 

    Focuses on the approval received by Cephalon Inc. from The U.S. Food and Drug Administration to market its narcolepsy drug Provigil. Potential of the drug in treating excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift-work sleep disorder; Expansion on the...

  • Recently Approved.  // Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p12 

    The article focuses on several drugs that are recently approved by the U.S. Food and Drug Administration (FDA). The Apidra drug from Aventis Pharma Ltd. has been approved to improve glycemic control in children four years and older with diabetes mellitus. CV Therapeutics Inc.'s Ranexa has been...

  • Cephalon's Nuvigil Gets Nod; Label Change, No New Trials. Osborne, Randall // BioWorld Today;4/3/2007, Vol. 18 Issue 64, p1 

    The article reports on the approval by the U.S. Food & Drug Administration of a drug called Nuvigil from Cephalon Inc. Nuvigil is designed to improve wakefulness in patients suffering from excessive sleepiness associated with narcolepsy and sleep disorders. Cephalon is required to add bold-face...

  • Biotechs Led in New Drugs for '08.  // BioWorld Today;1/5/2009, Vol. 20 Issue 1, p7 

    The article reveals that the biotechnology industry has surpassed big pharmaceutical firms in achieving U.S. Food and Drug Administration (FDA) approvals of new molecular entities (NME) and new biologics in 2008. 80 new drug applications (NDA) and biologic license applications (BLA) for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics